美国FDA药品数据库(U.S. FDA Drugs Database)
检索条件: 药品名称=PANCREAZE
符合检索条件的记录共5
1 页 当前第 1 页  返回检索页
1药品名称PANCREAZE
申请号022523产品号001
活性成分PANCRELIPASE (AMYLASE;LIPASE;PROTEASE)市场状态处方药
剂型或给药途径CAPSULE, DELAYED RELEASE;ORAL规格17,500USP/ UNITS;4,200USP/ UNITS;10,000USP/ UNITS
治疗等效代码参比药物
批准日期2010/04/12申请机构JANSSEN PHARMACEUTICALS INC
2药品名称PANCREAZE
申请号022523产品号002
活性成分PANCRELIPASE (AMYLASE;LIPASE;PROTEASE)市场状态处方药
剂型或给药途径CAPSULE, DELAYED RELEASE;ORAL规格43,750USP/ UNITS;10,500USP/ UNITS;25,000USP/ UNITS
治疗等效代码参比药物
批准日期2010/04/12申请机构JANSSEN PHARMACEUTICALS INC
3药品名称PANCREAZE
申请号022523产品号003
活性成分PANCRELIPASE (AMYLASE;LIPASE;PROTEASE)市场状态处方药
剂型或给药途径CAPSULE, DELAYED RELEASE;ORAL规格61,000USP/ UNITS;21,000USP/ UNITS;37,000USP/ UNITS
治疗等效代码参比药物
批准日期2010/04/12申请机构JANSSEN PHARMACEUTICALS INC
4药品名称PANCREAZE
申请号022523产品号004
活性成分PANCRELIPASE (AMYLASE;LIPASE;PROTEASE)市场状态处方药
剂型或给药途径CAPSULE, DELAYED RELEASE;ORAL规格70,000USP/ UNITS;16,800USP/ UNITS;40,000USP/ UNITS
治疗等效代码参比药物
批准日期2010/04/12申请机构JANSSEN PHARMACEUTICALS INC
5药品名称PANCREAZE
申请号022523产品号005
活性成分PANCRELIPASE (AMYLASE;LIPASE;PROTEASE)市场状态处方药
剂型或给药途径CAPSULE, DELAYED RELEASE;ORAL规格10,850USP UNITS;2,600USP UNITS;6,200USP UNITS
治疗等效代码参比药物
批准日期2014/03/07申请机构JANSSEN PHARMACEUTICALS INC